Effects of Dietary l-Arginine on Nitric Oxide Bioavailability in Obese Normotensive and Obese Hypertensive Subjects.
Obesity related hypertension is a major risk factor for resistant hypertension. We do not completely understand the mechanism(s) underlying the development of obesity related hypertension which hinders the development of novel treatment strategies for this condition. Data from experimental studies and small clinical trials indicate that transport of l-arginine, the substrate for nitric oxide (NO), and subsequent NO production are reduced in obesity induced hypertension. Reduced NO bioavailability can induce hypertension via multiple mechanisms. Mirmiran et al. recently analyzed data from a large population study and found that the association between dietary l-arginine and serum nitrate and nitrite was weakened in obese hypertensive subjects compared to obese normotensives. These data suggest that l-arginine dependent NO production is impaired in the former group compared to the latter which may represent a novel mechanism contributing to hypertension in the setting of obesity.
Baker IDI Heart and Diabetes Institute, VIC 3004 Melbourne, Australia. beverly.giam@bakeridi.edu.au.|Central Clinical School, Monash University, VIC 3004 Melbourne, Australia. beverly.giam@bakeridi.edu.au.
Beverly
B
Giam
Department of Biochemistry and Molecular Biology, Monash University, VIC 3004 Melbourne, Australia. sanjaya.kuruppu@monash.edu.
Sanjaya
S
Kuruppu
Baker IDI Heart and Diabetes Institute, VIC 3004 Melbourne, Australia. Geoff.Head@bakeridi.edu.au.
Geoffrey A
GA
Head
Baker IDI Heart and Diabetes Institute, VIC 3004 Melbourne, Australia. david.kaye@bakeridi.edu.au.
David M
DM
Kaye
Baker IDI Heart and Diabetes Institute, VIC 3004 Melbourne, Australia. Niwanthi.Rajapakse@bakeridi.edu.au.|Department of Physiology, Monash University, VIC 3004 Melbourne, Australia. Niwanthi.Rajapakse@bakeridi.edu.au.
Niwanthi W
NW
Rajapakse
D001119:Arginase / Q000378:metabolism; D001120:Arginine / Q000008:administration & dosage* / Q000097:blood; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D015220:Calcium Channels / Q000235:genetics / Q000378:metabolism; D002986:Clinical Trials as Topic; D004032:Diet; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications; D009566:Nitrates / Q000097:blood; D009569:Nitric Oxide / Q000097:blood / Q000493:pharmacokinetics*; D052250:Nitric Oxide Synthase Type III / Q000235:genetics / Q000378:metabolism; D009573:Nitrites / Q000097:blood; D009765:Obesity / Q000097:blood* / Q000150:complications; D012307:Risk Factors; D050916:TRPV Cation Channels / Q000235:genetics / Q000378:metabolism
D015220:Calcium Channels; D009566:Nitrates; D009573:Nitrites; D050916:TRPV Cation Channels; C422827:TRPV6 protein, human; D009569:Nitric Oxide; D001120:Arginine; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III; D001119:Arginase
">l-arginine transport; nitric oxide; obesity related hypertension